Gene Therapy and Gene Editing for β-Thalassemia.

ABSTRACT: After many years of intensive research, emerging data from clinical trials indicate that gene therapy for transfusion-dependent β-thalassemia is now possible. Strategies for therapeutic manipulation of patient hematopoietic stem cells include lentiviral transduction of a functional erythroid-expressed β-globin gene and genome editing to activate fetal hemoglobin production in patient red blood cells. Gene therapy for β-thalassemia and other blood disorders will invariably improve as experience accumulates over time. The best overall approaches are not known and perhaps not yet established. Gene therapy comes at a high cost, and collaboration between multiple stakeholders is required to ensure that these new medicines are administered equitably.

SUBMITTER: Christakopoulos GE 

PROVIDER: S-EPMC10355137 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature